Oxford University beaten to top spot in new 2026 ranking
The University of Oxford has missed out on the top spot in a new 2026 ranking.
Released this week, the 2026 Complete University Guide rankings have been released which feature the prestigious institution heavily.
These rankings offer a detailed look at how every UK university stacks up against key measures like student satisfaction, graduate prospects, research quality and more.
The annual rankings are widely followed by students, parents and educators and include a breakdown of each set of subjects.
READ MORE: David Beckham wins neighbour battle over £6m Cotswolds estate plans
Cambridge claimed top spot in the new university rankings.
Oxford has been beaten by bitter rival Cambridge in the overall ranking, finishing in second place.
Following the Oxbridge institutions are the London School of Economics and Political Science, the University of St Andrews and Durham University.
Imperial College London, Loughborough University and the University of Bath all follow in the new ranking.
The University of Warwick and Lancaster University round off the top 10 while the Universities of Exeter and York rank just outside.Oxford Mail readers can subscribe for just £4 for 4 months in this flash sale https://t.co/c4SlwFUiir
— Oxford Mail (@TheOxfordMail) June 10, 2025
Oxford has been ranked top of the Times Higher Education World University Rankings for nine consecutive years.
The prestigious institution was recently named the best in the world for three subjects in international rankings.
QS World University Rankings 2025 saw the prestigious institution claim the top spot for English Language and Literature, Anatomy and Physiology, and Geography.
In the new 2026 Complete University Guide rankings, Oxford was ranked best in the UK in 10 subjects.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation New preclinical data demonstrate that a single dose of INHBE siRNA leads to lower inflammation of adipose tissue with strong suppression of pro-inflammatory M1 macrophages in visceral fat in DIO mice, highlighting potential mechanistic insights into the risk reduction for type 2 diabetes (T2D) and coronary artery disease (CAD) suggested by human genetics CAMBRIDGE, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the presentation of preclinical data supporting WVE-007, its GalNAc-siRNA designed to silence INHBE mRNA, an obesity target with strong evidence from human genetics. The data demonstrate the ability of Wave's long-acting GalNAc-siRNA to reduce INHBE mRNA and Activin E protein, induce weight loss mainly through reduction of fat mass, and reduce pro-inflammatory macrophage recruitment in a diet-induced obese (DIO) mouse model. The data were highlighted today in an oral presentation at the American Diabetes Association's 85th Annual Scientific Sessions, taking place June 20 to 23, in Chicago. 'These exciting preclinical data highlighted in today's presentation both recapitulate human genetics findings and continue to support the potential of WVE-007 to drive weight reduction by reducing Activin E to induce lipolysis – or fat breakdown, preferentially reducing visceral fat, and decreasing inflammation of adipose tissue – all without impacting lean muscle mass. These data suggest a highly differentiated therapeutic profile with lower visceral fat, less insulin resistance and less inflammation, supporting potential for risk reduction of T2D, CAD and other obesity-related co-morbidities,' said Erik Ingelsson, MD, PhD, Chief Scientific Officer. 'Silencing of INHBE is an entirely orthogonal mechanism from GLP-1s, which are centrally acting and impact the digestive system and central nervous system to decrease appetite. If these preclinical data translate in the clinic, WVE-007 has the potential to transform the obesity treatment paradigm by delivering healthy weight loss, preservation of muscle mass, and infrequent dosing of once or twice a year. We are evaluating WVE-007 in our ongoing INLIGHT clinical trial in adults living with overweight or obesity, and we are on track to deliver the first clinical data in the second half of this year.' Human genetics provides strong evidence for INHBE as a therapeutic target. Individuals who have a protective loss-of-function variant in one copy of the INHBE gene have a healthier cardiometabolic profile, including less abdominal fat, lower triglycerides, and lower risk of type 2 diabetes and cardiovascular disease. These heterozygous carriers also exhibit favorable associations with liver traits, including reductions in cT1 (reflecting liver inflammation and fibrosis) and ALT (reflecting liver damage), with no impact on liver fat. The oral presentation titled, 'siRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile,' highlighted results from studies in DIO mice that evaluated monotherapy (INHBE-siRNA alone) as well as combination (INHBE siRNA and semaglutide), and maintenance (INHBE siRNA when semaglutide treatment is discontinued) treatment settings. Key results are as follows: A single dose of INHBE-siRNA led to robust target engagement, including reduction of INHBE mRNA and Activin E protein, a lipolysis suppressor that is upregulated in obesity. Liver INHBE mRNA was strongly correlated with serum Activin E levels following INHBE-siRNA treatment. A single dose of INHBE-siRNA led to weight loss on par with semaglutide. There was a decrease in diet-induced visceral adipose mass and shrinkage of adipocytes compared with PBS treatment, supporting the restoration of healthy adipose tissue with this mechanism of action. Muscle mass was preserved. Infiltration of activated macrophages in visceral adipose was significantly decreased by a single dose of INHBE-siRNA compared with PBS controls. INHBE-siRNA also significantly reduced proinflammatory M1 macrophage (CD11c positive) recruitment while sustaining levels of anti-inflammatory M2 macrophages in visceral fat, indicating an overall shift away from a pro-inflammatory state. When administered as an add-on to semaglutide, a single dose of INHBE-siRNA doubled the amount of weight loss, highlighting potential for combination treatment. Wave's INHBE siRNA curtailed rebound weight gain when semaglutide treatment was discontinued, highlighting its potential as an off-ramp and maintenance treatment following GLP-1 treatment. The full presentation can be accessed by visiting 'Scientific Presentations' on the Investors section of the Wave Life Sciences website: About Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and Obesity, as well as several preclinical programs utilizing the company's broad RNA therapeutics toolkit. Driven by the calling to 'Reimagine Possible', Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding our expectations for WVE-007 and the anticipated therapeutic benefits thereof; the anticipated timing of clinical data from our INLIGHT clinical trial of WVE-007; the novelty of our approach to silence INHBE mRNA in order to achieve healthy, sustainable weight loss and the potential for once- or twice-yearly dosing; the potential benefits of WVE-007 over existing obesity therapies; the potential of WVE-007's mechanism (INHBE) as a novel and unique obesity treatment to induce fat loss, preserve muscle, and drive weight loss; our understanding of our preclinical data for WVE-007 and our expectations of how such data will translate in humans; beliefs that Wave's portfolio of RNA medicines is differentiated, potentially best-in-class and potentially transformative; the broad potential of Wave's RNA medicines pipeline and oligonucleotide chemistry and any benefits that may arise as a result thereof. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled 'Risk Factors' in Wave's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. Contact:Kate RauschVP, Corporate Affairs and Investor Relations+1 617-949-4827Investors:InvestorRelations@ Media:MediaRelations@ in to access your portfolio
Yahoo
an hour ago
- Yahoo
Florian Wirtz joins list of most expensive soccer signings in history
Florian Wirtz became one of the most expensive players in soccer history when the Germany playmaker joined Liverpool from Bayer Leverkusen on Friday for a fee of up to 116 million pounds ($156 million). Neymar: $262 million (222 million euros) Advertisement Paris Saint-Germain shattered the world-record transfer fee by signing the Brazil superstar from Barcelona in August 2017. It was more than double the outlay of Manchester United to sign Paul Pogba from Juventus for $116 million a year earlier. It remains the record transfer fee. ___ Kylian Mbappé: $216 million (180 million euros) A few weeks after buying Neymar, PSG also secured a loan deal for Mbappé — then the rising star of French soccer playing for Monaco — that included the option to make the move permanent in 2018. PSG did so, making it an outlay of nearly $500 million on two players. ___ Philippe Coutinho: $192 million (160 million euros) Advertisement Flush with cash after selling Neymar a year earlier, Barcelona spent most of it in a deal to buy Brazil playmaker Coutinho from Liverpool for a Spanish record fee. ___ Moises Caicedo: $146 million (115 million pounds) The Ecuador midfielder's move was previously the most expensive deal by a British club, with Chelsea buying him from Brighton in August 2023. ___ João Félix: $140 million (126 million euros) Atletico Madrid triggered a buyout clause in Félix's contract to sign the Portugal forward from Benfica in August 2019. ___ Jude Bellingham: $139 million (128.5 million euros) The England star got his big move to Real Madrid from Borussia Dortmund in June 2023, for an initial up-front fee of 103 million euros plus add-ons linked to performance. Advertisement ___ Antoine Griezmann: $134 million (120 million euros) Atletico could afford to sign Félix after selling France forward Griezmann to Barcelona for a similar fee a few weeks earlier. ___ Neymar: $98 million (90 million euros) Outside from Europe, the biggest transfer deal also involved Neymar when he joined Al Hilal, a team in the Saudi Pro League, from Paris Saint-Germain in August 2023. That came at the height of Saudi Arabia's push to sign high-end soccer talent to ignite the oil-rich state's domestic league. ___ AP soccer: Steve Douglas, The Associated Press
Yahoo
2 hours ago
- Yahoo
David Hopkinson obituary
My friend and former colleague David Hopkinson, who has died aged 89, was director of the Medical Research Council's human biochemical genetics unit at University College London from 1976 until its closure in 2000. Hoppy, as he was universally known, had joined the unit at its inception in 1962 because in an earlier, more junior, position he had been one of the first medical scientists to describe molecular differences in human enzymes, long before DNA sequence differences were known about. The unit was established to research the extent and significance of genetic variation to human health. As its head, Hoppy expanded its focus to gene mapping and disease genetics while also moving into the new science of gene cloning and DNA sequencing. Born in Chesterfield, Derbyshire, to Albert Hopkinson, an iron and steelworks foreman, and Lilian (nee Siddal), a dressmaker, he went to Chesterfield grammar school, which fostered his early interest in organic chemistry. After completing a natural sciences degree at Cambridge University he qualified in medicine at the London hospital in 1959, working there until he joined the human biochemical genetics unit three years later. Hoppy was recruited by its inaugural head, Prof Harry Harris, becoming his right-hand man responsible for many of the unit's innovative experimental approaches, including developing novel methods of enzyme detection and electrophoresis. The unit moved in 1965 from its initial base at King's College to UCL, where I joined the unit three years later to study for a PhD under Harris. Hoppy remained there for the rest of his career. He published widely, and played an important part in teaching and supervision, being made full professor of London University in 1990. Twenty five years after his retirement, his role as mentor is remembered with great warmth by his former staff and students. Hoppy read widely and appreciated drama and music. A practical man who took pleasure in manual labour, he was an accomplished gardener and delighted in propagating plants and growing vegetables. He also enjoyed summers hiking in the Swiss Alps, and was a keen birdwatcher. In retirement, he studied architecture and German, and gained a first-class degree in geology at the Open University. He also spent many years as a volunteer at Chilterns' Citizens Advice in Chesham, Buckinghamshire. He is survived by his second wife, Prof Yvonne Edwards, and by three children, Paul, Susan and Ian, from his first marriage, to Josephine (nee Manze), which ended in divorce, and four grandchildren.
